ORBIMED ADVISORS LLC 13D and 13G filings for Fusion Pharmaceuticals Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-05-16 4:28 pm Unchanged |
2023-05-11 | 13D | Fusion Pharmaceuticals Inc. FUSN |
ORBIMED ADVISORS LLC | 2,930,670 4.600% |
0 (Unchanged) |
Filing |
| 2023-02-28 5:09 pm Sale |
2023-02-16 | 13D | Fusion Pharmaceuticals Inc. FUSN |
ORBIMED ADVISORS LLC | 2,930,670 4.700% |
-67,311 (-2.25%) |
Filing |
| 2020-07-06 5:57 pm Purchase |
2020-06-30 | 13D | Fusion Pharmaceuticals Inc. FUSN |
ORBIMED ADVISORS LLC | 2,997,981 7.200% |
2,997,981 (New Position) |
Filing |